Osteonecrosis in children with acute lymphoblastic leukemia

Kunstreich, Marina; Kummer, Sebastian; Laws, Hans-Juergen; Borkhardt, Arndt; Kuhlen, Michaela

doi:10.3324/haematol.2016.147595

Cited by 94 publications

(139 citation statements)

References 83 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Suspicion of osteonecrosis often arises in the presence of clinical signs such as pain and loss of motion, though some studies have described the use of MRI to prospectively diagnose asymptomatic osteonecrosis [39]. Demographic factors associated with increased risk of osteonecrosis include age 10 to 20 years, female sex and European ancestry [84]. Osteonecrosis has been generally attributed to the effect of the large doses of corticosteroids given during ALL therapy.…”

Section: Bony Toxicitymentioning

confidence: 98%

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia

Maxwell

Cole

2017

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Multiple studies have examined the toxicities of the primary chemotherapeutic agents used to treat childhood ALL in relation to host genetic factors. However, few results have been replicated independently, largely due to cohort differences in ancestry, chemotherapy treatment protocols, and definitions of toxicities. To date, there is only one widely accepted clinical guideline for dose modification based on gene status: thiopurine dosing based on TPMT genotype. Based on recent data, it is likely that this guideline will be modified to incorporate other gene variants, such as NUDT15. We highlight genetic variants that have been consistently associated with TRT across treatment groups, as well as those that best illustrate the underlying pathophysiology of TRT. In the coming decade, we expect that survivorship care will routinely specify screening recommendations based on genetics. Furthermore, clinical trials testing protective interventions may modify inclusion criteria based on genetically determined risk of specific TRTs.

show abstract

Section: Bony Toxicitymentioning

confidence: 98%

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia

Maxwell

Cole

2017

Curr Hematol Malig Rep

View full text Add to dashboard Cite

show abstract

“…Adolescents are at increased risk of both hyperlipidemia 8 and ON. 1 We found cut-off levels for both peak-TG and peak-CH, identifying groups of patients with exceptionally high incidence of ON. This suggests that, apart from age, peak-TG and peak-CH are important predictors.…”

Section: P=0495)mentioning

confidence: 99%

“…Interventional studies are needed to elucidate whether lowering TG and CH during combined PEG-ASP and dexamethasone therapy can reduce the risk of ON. Signe Sloth Mogensen, 1 Kjeld Schmiegelow, …”

Section: P=0495)mentioning

confidence: 99%

Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia

et al. 2017

View full text Add to dashboard Cite

“…Osteonecrosis (ON) is characterized by nonseptic destruction of the bone and it is a known complication of therapy in children and young adults treated for acute lymphoblastic leukemia (ALL) . ON primarily affects weight‐bearing joints and causes pain and decreased mobility .…”

Section: Introductionmentioning

confidence: 99%

Early presentation of osteonecrosis in acute lymphoblastic leukemia: Two children from the Nordic and Baltic cohort

Mogensen

Harila‐Saari

Frandsen

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Osteonecrosis (ON) is usually considered treatment related in patients with acute lymphoblastic leukemia (ALL). We report two patients with presentation of ON at the time of ALL diagnosis. Both were females and diagnosed with ALL at age 8 and 14 years. In the latter, some symptoms and radiologically verified ON in both knees were still present after the end of ALL therapy. No pediatric patients have previously been reported with ON presenting before initiation of ALL therapy.

show abstract

Osteonecrosis in children with acute lymphoblastic leukemia

Cited by 94 publications

References 83 publications

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia

Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia

Early presentation of osteonecrosis in acute lymphoblastic leukemia: Two children from the Nordic and Baltic cohort

Contact Info

Product

Resources

About